Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


WHO Urges Pause On COVID-19 Booster Shots

Executive Summary

The pharmaceutical industry group, IFPMA, believes that a massive scale-up in manufacturing means booster shots will not necessarily “exacerbate inequities”.

You may also be interested in...

WHO Director General ‘Appalled’ At Industry Approach To COVID-19 Vaccines

World Health Organization director general says poorer countries should not have to be satisfied with richer country “left overs.”

UK Approves Booster Doses For Two COVID-19 Vaccines

AstraZeneca's Vaxzevria and Pfizer/BioNTech's vaccine can be used as "booster" vaccines in the UK, pending advice on a possible vaccination campaign from the government's advisory committee. 

EU Pilots New 'Stepwise' Approach To Pediatric Investigation Plans

New EU guidance has been published to help the European Medicines Agency and drug developers agree on the conduct of pediatric investigation plans (PIPs) when crucial information is not yet available. 


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts